Insulet's Strategic Pivot: Targeting the Type 2 Diabetes Market

ACTON, Mass. – June 06, 2026

Insulet Corporation, the maker of the tubeless Omnipod insulin pump, has unveiled clinical data that signals more than just an incremental product upgrade. The results, presented at the influential American Diabetes Association's 86th Scientific Sessions, detail a two-pronged advance: a more powerful algorithm in its next-generation Omnipod 6 system and, more strategically, a purpose-built, fully automated system designed to conquer the vast and challenging type 2 diabetes market. This isn't just about better glucose control; it's a calculated maneuver to redefine the boundaries of automated insulin delivery and secure a dominant position in the next phase of diabetes technology.

The Next Leap in Automation: Sharpening the Algorithm

For its core user base of people with type 1 diabetes, Insulet showcased the STRIVE pivotal trial for its upcoming Omnipod 6 system. The data demonstrates a clear evolution from its successful Omnipod 5, a system already popular for its tubeless, wearable design. The key innovation lies in a more responsive and powerful algorithm. “Omnipod 6 represents one of our biggest steps forward yet, with greater personalization and responsiveness to hyperglycemia, by delivering up to 50% more automated insulin,” said Dr. Trang Ly, Insulet’s Senior Vice President and Chief Medical Officer.

This increased automated insulin capacity translated into tangible clinical improvements. In the trial, adults and adolescents with type 1 diabetes saw their "time in tight range" (glucose levels between 70-140 mg/dL) increase by a meaningful 7 percentage points compared to the current Omnipod 5. Perhaps more revealing of the system's strategic design is its performance under real-world conditions. During a phase of the study where participants were encouraged to bolus less frequently for meals, the Omnipod 6 maintained strong glycemic control, achieving 76% time in range with 2.2 fewer manual boluses per day.

This feature directly targets a major pain point in diabetes management: the cognitive burden and constant vigilance required. By building an algorithm robust enough to compensate for missed meal announcements, Insulet is advancing its "Liveable Technology" philosophy—creating devices that demand less from the user while delivering more. This focus on reducing user effort is a critical competitive differentiator, aiming to improve not just clinical metrics but the overall quality of life for its users. The system maintained a strong safety profile, with no instances of severe hypoglycemia or diabetic ketoacidosis, clearing a crucial hurdle for any new insulin delivery technology.

The Untapped Frontier: Cracking the Type 2 Diabetes Code

While Omnipod 6 represents a significant enhancement for the established type 1 market, the true long-term strategic play revealed at the conference is the company's fully closed-loop (FCL) system for type 2 diabetes. This population, which dwarfs the type 1 market in size, has historically been underserved by advanced automated insulin delivery (AID) systems due to different physiological needs and barriers to adoption, such as the complexity of mealtime insulin calculations.

Insulet's EVOLUTION 3 study confronts this challenge head-on. The FCL system is designed to be largely "hands-off," automating mealtime insulin delivery without requiring the user to announce meals or perform complex calculations. This is a potential game-changer. The study enrolled a diverse group of adults with type 2 diabetes who, despite intensive management, had a high baseline HbA1c of 8.1%. The FCL system delivered a 12% absolute improvement in time in range, bringing participants to 64% on average, with minimal hypoglycemia.

The financial and physiological implications are equally profound. Participants saw their total daily insulin dose drop dramatically from 86 units to 58 units, all while experiencing no weight gain—a common side effect of intensified insulin therapy that is a major concern for this patient population. The system's success is not just clinical; it's behavioral. A reported 86% of participants were satisfied or highly satisfied, noting a reduced burden of care. “Our fully closed-loop system for type 2 diabetes is intentionally designed to unlock barriers to AID by managing mealtime insulin and simplifying workflows to expand clinic adoption,” Dr. Ly stated, underscoring the strategic intent. With a planned 2027 FDA submission and a target 2028 commercial launch, Insulet is on a clear path to enter a market segment its competitors have yet to fully penetrate.

A Calculated Move in a Crowded Field

Insulet's announcements do not occur in a vacuum. The diabetes technology landscape is fiercely competitive, with rivals like Medtronic, Tandem Diabetes Care, and Beta Bionics all pushing the boundaries of automation. Medtronic continues to leverage its deep market penetration with its MiniMed series, while Tandem’s t:slim pumps with Control-IQ technology are a major force. However, Insulet's tubeless patch pump remains a powerful differentiator, offering a level of discretion and freedom that resonates strongly with users.

The strategic pivot towards type 2 diabetes sets Insulet apart. While competitors also have their sights on this market, Insulet’s dedicated FCL system, with its focus on eliminating manual meal boluses, is a targeted solution for a specific, unmet need. This move is further buoyed by a significant tailwind from the medical establishment itself. The ADA's newly updated 2026 Standards of Care now recommend AID systems as the preferred delivery method for all people with type 1 diabetes and for those with type 2 on multiple daily injections, effectively broadening the addressable market overnight. This endorsement provides regulatory and clinical air cover for Insulet's expansion strategy.

By focusing on a system that simplifies one of the most complex aspects of insulin therapy for the type 2 population, the company is not just competing on algorithmic precision but on accessibility and ease of use—a battle it is well-positioned to win given its foundational product design.

The Path from Lab to Life: Strategy and Execution

Bringing these innovations to market requires navigating a complex regulatory and commercial landscape. The company's plan to file for a 510(k) clearance for the FCL system in 2027 suggests a strategy to leverage existing predicate devices, potentially accelerating its path to market compared to a more arduous Premarket Approval (PMA) process. This timeline indicates a high degree of confidence in both the technology and the regulatory pathway.

From a financial standpoint, this strategy is built on a solid foundation. With a healthy balance sheet and consistent profitability, Insulet is well-capitalized to fund the final stages of development and a large-scale commercial launch. Analysts note that with only 40-45% of the type 1 population currently using automated devices, significant growth potential remains even in its core market. The expansion into the much larger type 2 market represents an exponential growth opportunity that could redefine the company's valuation and market leadership in the coming years.

Insulet’s dual-pronged strategy—refining its offering for the sophisticated type 1 market while building a simplified, accessible solution for the type 2 population—is a clear and ambitious plan. The clinical data provides the proof of concept, but the true test will be in the execution of its go-to-market strategy, transforming breakthrough technology into a dominant market presence that fundamentally changes how millions of people manage their diabetes.